Factor Xa
19 drugs Cardiovascular
10
approved indications
19
Approved Drugs
10
Companies
28
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (10 companies)
✓ All 19 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (28 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Pfizer 6 drugs
Fresenius Kabi 3 drugs
Baxter 2 drugs
By Therapeutic Area
Cardiovascular 14 drugs
Other 5 drugs
Drugs by Company PRO
Pfizer 6 drugs
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERHEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINERHEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINERHEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINERHEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERHEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Fresenius Kabi 3 drugs
Baxter 2 drugs
Bristol-Myers Squibb 2 drugs
Johnson & Johnson 1 drug
ALEMBIC 1 drug
DAIICHI SANKYO INC 1 drug
Viatris 1 drug
Dr. Reddy's 1 drug
CORMEDIX 1 drug
By Therapeutic Area
Cardiovascular 14 drugs
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, RIVAROXABAN, HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM IN PLASTIC CONTAINER +10 more
Other 5 drugs
XARELTO, DEFENCATH, HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER +1 more
Indications Treated
Venous ThrombosisPulmonary EmbolismDeep Venous ThrombosisAtrial FibrillationDisseminated Intravascular CoagulationPeripheral Arterial EmbolismCardiovascular DiseaseCoronary Artery DiseasePeripheral Artery DiseaseMyocardial InfarctionStrokeLimb IschemiaStroke PreventionDeep Vein ThrombosisSystemic EmbolismStroke and systemic embolism risk reduction in nonvalvular atrial fibrillationTreatment of deep vein thrombosis (DVT)Treatment of pulmonary embolism (PE)Reduction in the risk of recurrence of DVT and PEProphylaxis of DVT in patients undergoing knee or hip replacement surgeryProphylaxis of venous thromboembolism (VTE) in acutely ill medical patientsReduction of major cardiovascular events in patients with coronary artery disease (CAD)Reduction of major thrombotic vascular events in patients with peripheral artery disease (PAD)Treatment of VTE and reduction in the risk of recurrent VTE in pediatric patientsThromboprophylaxis in pediatric patients with congenital heart disease after the Fontan procedureCatheter-Related Bloodstream InfectionKidney FailureVenous Thromboembolism